It picks up lymph nodes, visceral metastases, bone metastases, and does it at a very low PSA level we're talking levels that are even less than 0.5 ng/mL and down to the 0.2 ng/mL range, so it's much more sensitive for detection of prostate cancer. I think the key advantage to PSMA-PET imaging is the fact that it’s a lot more sensitive than standard imaging. What is the advantage of PSMA imaging over standard imaging? That being said, next-generation PET imaging, whether it's fluciclovine (fluciclovine F 18 ) or PSMA-PET imaging, has really now arrived in the United States. And as you know, in the United States, regulatory approvals for things like drugs/therapeutics are probably easier than in other places, such as Europe however, regulatory approval for imaging agents, seems to require a higher bar. So it's not completely new, it's just newer to the United States. This includes much work that was done in Germany, and it’s use in Australia is widespread. PSMA PET imaging has been available and used outside of the United States for quite some time. Please discuss the background of PSMA PET imaging. Yu is a professor in the Department of Medicine, Division of Oncology, University of Washington and Fred Hutchinson Cancer Research Center. Yu, MD, discusses the background of PSMA-PET the first FDA-approved PSMA agent, gallium 68 PSMA-11 (Ga 68 PSMA-11) the emerging PSMA PET imaging agent 18F-DCFPyL the theranostic 177Lu-PSMA-617 and more. PSMA-PET imaging has emerged as a new frontier in prostate cancer diagnosis and treatment.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |